Firefly reported research using resting EEG and cognitive EEG (ERP) brain scans collected on its FDA 510(k)-cleared Evoke System to potentially distinguish among three ADHD subtypes: hyperactive/impulsive, inattentive, and combined. The announcement did not state that clinical results have already been presented or that they will be presented in the future. The company cited a U.S. ADHD treatment market estimated at more than USD 10 billion. Firefly said its EEG/ERP work is being developed alongside an EEG/ERP brain foundation model trained on a repository of more than 191,000 brain scans.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Firefly Neuroscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603130755PRIMZONEFULLFEED9671597) on March 13, 2026, and is solely responsible for the information contained therein.